RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)

RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)

The NOFO RFA-NS-25-021 is a translational, milestone-driven NIH funding opportunity tied to the BRAIN Initiative. It is designed to support teams moving a neurotechnology concept toward first-in-human or early clinical testing through a staged UG3/UH3 cooperative agreement structure. The funding focus is on next-generation CNS recording and modulation devices, especially projects that require a Serious Risk IDE pathway and then transition into a small clinical study phase.

Unlike standard research grants that mainly reward discovery work, this program explicitly links funding to implementation, regulatory readiness, and translation to clinical use. In practical terms, it is not only about whether the science is strong; it is about whether the application shows a plausible sequence of milestones and a credible path to an FDA IDE and early human testing.

This is a high-effort opportunity for teams with serious intent to progress toward a real-world device pathway.

Key details at a glance

Why this is a distinct opportunity type

This NOFO sits at the boundary between preclinical engineering and clinical translation. The title says it directly: it covers recording and modulation devices for central nervous system disorders. The program text clarifies that only Significant Risk (SR) clinical studies that require an investigational device exemption (IDE) are supported. That detail matters because it filters out safer, non-significant-risk studies that can proceed under different regulatory pathways.

The NOFO is also part of a broader ecosystem within NIH BRAIN funding: there is a companion RFA-NS-25-022 for UH3 studies in related domains, and this one is positioned as a preclinical-to-clinical pipeline with the UG3 phase handling translational groundwork and milestone testing. Applicants can use this structure to show a staged plan where early translational work de-risks the later clinical work.

Because this is an explicit cooperative agreement, NIH program staff are not passive reviewers only. The NOFO states that there is substantial federal involvement after award through guidance, coordination, and progress monitoring. For teams looking for autonomy-first funding, that is a tradeoff to understand: you get access to NIH-level stewardship and likely stronger program direction, but you also accept tighter milestone governance.

What exactly the program supports

The opportunity supports translational activities and small clinical studies with clearly defined paths for CNS device development. The scope includes:

• Non-clinical development work needed before human use,
• preparation for and execution of SR IDE submissions,
• and a clinically feasible project plan for a small study phase when appropriate.

The NOFO emphasizes milestone-based progress and allows applications that do not propose clinical trial work, as clinical trial status is optional. That means both teams with only non-clinical translational activity and teams ready to move into a limited clinical phase can apply under this NOFO, as long as their plan is realistic and tied to the stated milestones.

The program is particularly relevant for:

• device teams already near a mature prototype stage,
• groups with access to manufacturing or technical partners,
• academic labs working with clinical investigators,
• and companies pursuing CNS indications that can demonstrate a constrained feasibility plan.

The NOFO also supports projects that can leverage established BRAIN Public-Private Partnership (PPP)-type collaborations, but those are optional. Existing collaborations with device manufacturers are acceptable. The official text is clear: your proposal should show evidence of practical collaboration, whether via BRAIN PPP routes or alternate partner pathways.

Eligibility logic and common misconceptions

Many people assume “BRAIN funding” means only NIH intramural programs or only large universities can apply. The NOFO is much broader in organizational structure. Eligible organizations include higher education institutions, nonprofits (with and without 501(c)(3)), small businesses, other for-profits, and a range of government and regional entities. In practice, this means a consortium model is possible when each institution can justify its role in the translational chain.

Important constraints are also explicit:

• Non-U.S. organizations are not eligible to apply as applicants,
• U.S.-based organizations with foreign components are allowed,
• foreign entities themselves are not
• registrations through NIH systems and federal portals must be complete before the due date.

The registration stack is not optional: applicants must have SAM, eRA Commons, and Grants.gov readiness in place by submission. The NOFO flags this as a hard precondition; late registrations are not accepted as an excuse for late or noncompliant submissions.

Another common misconception is that only clinically trained teams can apply. In practice, the NOFO is designed for transdisciplinary teams. It explicitly welcomes academics, industry collaborators, regulatory-aware teams, and organizations that can demonstrate a complete path from device development to clinical readiness.

The most important eligibility-adjacent pass/fail issue is not a checkbox item but a design issue: it must be one CNS disorder focus, and clinical design choices should match that disease indication. The NOFO repeatedly asks for focus and specificity in outcomes, endpoint definition, and translation timelines.

Award structure, budget, and the milestone contract

The grant-style headline (“up to $500,000 direct costs/year in UG3” and “should rarely exceed $1,500,000 direct costs/year in UH3”) can look generous, but teams often misread this as a fixed stipend package. The NOFO makes it explicit that budget sizes must reflect need and that application budgets should not be inflated.

A typical approved structure is:

• UG3 phase: proof and translational prep, with an annual project period not exceeding one year,
• UH3 phase: transition to later stage clinical activity, with annual project period not exceeding four years,
• total project length: no more than five years across both phases.

This staged architecture changes how you write your budget narrative. In UG3 you should allocate for regulatory preparation, design controls, feasibility, and early human-subject pathways; in UH3 you must show the continuity into clinical operations and the feasibility to execute within revised milestones.

The NOFO notes that funding decisions are tied to milestones and can be discontinued if goals are not met. It specifically states progress is reviewed against quantitative milestones and progress reporting, and continuation decisions can be based on scientific strength plus practical execution progress.

Teams should therefore avoid writing milestone-driven work packages as generic checklists. Milestones must be measurable, realistic and tied to regulatory decisions (especially the ability to advance to an IDE and move to clinical execution). Also, the transition decision is not purely scientific; it is administrative and programmatic too.

Application requirements that decide pass/fail quickly

Even experienced research teams lose time here.

System and registration requirements

Applications must be submitted electronically through NIH-accepted channels: NIH ASSIST, Grants.gov Workspace, or an institutional eRA Commons/Grants.gov system-to-system flow. Paper submissions are not accepted.

Required registrations:

• SAM (including UEI and active status),
• eRA Commons account set up for all PD/PI relationships,
• Grants.gov registration tied to SAM.

If your organization cannot complete these by deadline, no late exception exists.

Core technical submission requirements

The NOFO is strict on packaging, attachments, and page limits:

• Gantt chart (1 page max, required),
• IP strategy (3 pages max, required),
• Needs Assessment (3 pages max, required),
• Long-term Patient Care plan (3 pages max, required),
• optional schematics and IRB communications attachments with limits.

A frequent failure mode is missing one required attachment or exceeding the page cap. That is a non-responsiveness error, not a review weakness, and can remove an otherwise strong application.

What reviewers expect in the science narrative

The single Specific Aims and Research Strategy sections are expected to be tightly mapped to regulatory and translation logic. The NOFO expects:

• one CNS indication focus,
• clear significance section with current standard-of-care gap and unmet need,
• proof-of-concept data for proposed device function,
• realistic sample strategy, and
• a concrete path to IDE submission and IRB readiness.

For clinical applications, the reviewer panel evaluates whether the approach is feasible, whether inclusion/exclusion and participant planning are justified, and whether outcomes are clinically meaningful.

Review process: what determines competitiveness

This NOFO uses normal NIH peer review mechanics but overlays requirement-specific criteria:

1. Scientific importance and rigor,
2. Rigor and feasibility,
3. Investigator and environment fit,
4. Additional items like IP plan, human-substances protections, milestone realism, data and clinical safety controls.

Reviewers are also asked to evaluate:

• whether translation milestones can lead to meaningful regulatory progress,
• whether clinical plans include realistic recruitment and retention assumptions,
• whether long-term patient care responsibilities are planned,
• whether IP barriers are identified early.

The NOFO notes that as in many NIH competitions, not all compliant applications are equally funded. Applications may be screened for top-tier scientific merit before full discussion. If selected for funding after review, the second-level advisory process and budget availability still apply.

A practical implication: scientific quality must be high, but compliance quality can be equally decisive. Both dimensions are scored and interpreted together.

Preparation strategy for teams applying in 2026-2027

The best strategy is to design from the review form backward:

• Build milestone maps first, then write project aims.
• Define regulatory gates explicitly: which action occurs when, and what evidence supports each gate.
• Prepare partner letters in advance if your device or IP is not owned by the applying institution.
• Confirm that your supporting data include a device description and preclinical evidence that demonstrates translational plausibility.
• Draft a data management and sharing plan aligned with NIH BRAIN sharing expectations.

If you are considering BRAIN PPP-like collaboration, obtain letters or draft engagement evidence early. The NOFO indicates collaboration feasibility is a recurring review point. Proposals that mention a partner in principle but cannot show practical engagement can underperform.

A strong application typically includes:

• a narrow, disease-specific technical narrative,
• a realistic regulatory timeline with contingency planning,
• an implementation budget tied directly to milestones,
• and explicit transitions between discovery, IDE readiness, and clinical activity.

Because this is a UG3/UH3 format, teams should avoid writing a single-phase proposal. If your project does not naturally flow to a stage-gate logic, your write-up will look incoherent.

Common mistakes to avoid before submission

1. Overly broad disease scope. The NOFO asks for one CNS indication and consistent outcomes around that indication.

2. Ignoring registration prerequisites. Missing SAM/eRA/Grants.gov readiness is a practical disqualifier.

3. Underbuilding the IP and partnership evidence. The NOFO explicitly checks if IP constraints and partner permissions are clear.

4. Treating milestones as vague progress text. Milestones must be quantitative and actionable.

5. Submitting compliance errors. Missing attachments, exceeding page limits, or violating content format rules leads to withdrawal.

6. Weak long-term patient care considerations. This is explicitly required in a separate attachment and evaluated for adequacy.

7. Assuming clinical-only scope. Because clinical trial status is optional, a proposal can still be compelling without a full trial, if the non-clinical-to-translation path is strong.

8. Weak team governance. The NOFO specifically asks evaluators to assess team governance and scientific steering structure.

Frequently asked practical questions

Is this only for projects that already have a finished medical device?

Not necessarily. It is for projects at a translational stage where device development, safety characterization, and regulatory planning are mature enough to support an IDE timeline.

Can non-academic teams apply?

Yes. Small and larger for-profit organizations are eligible, as long as organizational and regulatory prerequisites are met and the team is appropriate for research execution.

Can this be used for a first-in-human device trial?

Yes, if structured correctly. The NOFO allows first-in-human studies without requiring prior human data, but it still expects a credible preclinical basis and a clear regulatory pathway.

Is the funding guaranteed to continue into UH3?

No. UH3 transition depends on milestone performance, quality of progress, and program/portfolio-level factors.

How strict is the budget cap?

UG3 has a direct cost cap of $500,000 per year, and UH3 should rarely exceed $1,500,000 per year. Reviewers expect those budgets to be tied to scope and necessity, not arbitrary inflation.

Why this is worth monitoring for 2026 and 2027

If your work sits at the junction of engineering and clinical neuroscience, this NOFO is among the most concrete U.S. federal routes for early-stage translational funding into human-focused neurotechnology work. It is especially practical for teams that already have a viable prototype and now need structured support for regulatory milestones and early clinical transition.

As of the snapshot date (2026-05-21), the opportunity has a relevant September 2026 due date and an expiration date at the end of September 2026, placing it squarely in the 2026-2027 planning window. This makes it timely for teams already in late preclinical development.

The biggest strategic difference between this and many grant programs is that funding is tied to execution discipline. You are not rewarded only for novelty; you are rewarded for disciplined progression under measurable milestones.

Official links and source references

• NIH NOFO: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-021.html
• NIH Brain Initiative: https://www.braininitiative.nih.gov/
• BRAIN Initiative PPP resources: https://braininitiative.nih.gov/research/neural-recording-modulation/public-private-partnerships-program
• NIH Application Guide: https://grants.nih.gov/grants/how-to-apply-application-guide
• ClinicalTrials.gov requirements and reporting context as described in NIH policy pages